Cited by 129Cannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

Open access

Patricio, Felipe, Morales-Andrade, Alan Axel, Patricio-Martínez, Aleidy, Limón, Ilhuicamina Daniel·2020·Frontiers in Pharmacology

DOI 10.3389/fphar.2020.595635PMC PMC7770114

Open this paper in CoChat — free account Open PDF

Abstract

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a pharmacological alternative for treating various central nervous system (CNS) disorders. Interestingly, cannabinoid receptors (CBRs) are highly expressed in the basal ganglia (BG) circuit of both animals and humans. The BG are subcortical structures that regulate the initiation, execution, and orientation of movement. CBRs regulate dopaminergic transmission in the nigro-striatal pathway and, thus, the BG circuit also. The functioning of the BG is affected in pathologies related to movement disorders, especially those occurring in Parkinson’s disease (PD), which produces motor and non-motor symptoms that involving GABAergic, glutamatergic, and dopaminergic neural networks. To date, the most effective medication for PD is levodopa (l-DOPA); however, long-term levodopa treatment causes a type of long-term dyskinesias, l-DOPA-induced dyskinesias (LIDs). With neuromodulation offering a novel treatment strategy for PD patients, research has focused on the endocannabinoid system (ECS), as it participates in the physiological neuromodulation of the BG in order to control movement. CBRs have been shown to inhibit neurotransmitter release, while endocannabinoids (eCBs) play a key role in the synaptic regulation of the BG. In the past decade, cannabidiol (CBD), a non-psychotropic phytocannabinoid, has been shown to have compensatory effects both on the ECS and as a neuromodulator and neuroprotector in models such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and reserpine, as well as other PD models. Although the CBD-induced neuroprotection observed in animal models of PD has been attributed to the activation of the CB1 receptor, recent research conducted at a molecular level has proposed that CBD is capable of activating other receptors, such as CB2 and the TRPV-1 receptor, both of which are expressed in the dopaminergic neurons of the nigro-striatal pathway. These findings open new lines of scientific inquiry into the effects of CBD at the level of neural communication. Cannabidiol activates the PPARγ, GPR55, GPR3, GPR6, GPR12, and GPR18 receptors, causing a variety of biochemical, molecular, and behavioral effects due to the broad range of receptors it activates in the CNS. Given the low number of pharmacological treatment alternatives for PD currently available, the search for molecules with the therapeutic potential to improve neuronal communication is crucial. Therefore, the investigation of CBD and the mechanisms involved in its function is required in order to ascertain whether receptor activation could be a treatment alternative for both PD and LID.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.595635

Cites

240 of 240 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–240 of 240

A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors
Echeverry, C., Prunell, G., Narbondo, C., de Medina, V. S., Nadal, X., Reyes-Parada, M. I., & Scorza, C. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00277-y · Cited by 64
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats
Martinez, A. A., Morgese, M. G., Pisanu, A., Macheda, T., Paquette, M. A., Seillier, A., Cassano, T., Carta, A. R., & Giuffrida, A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.024 · Cited by 62
A Single Centre, Placebo-Controlled, Four Period, Crossover, Tolerability Study Assessing, Pharmacodynamic Effects, Pharmacokinetic Characteristics and Cognitive Profiles of a Single Dose of Three Formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), Plus a Two Period Tolerability Study Comparing Pharmacodynamic Effects and Pharmacokinetic Characteristics of a Single Dose of a Cannabis Based Medicine Extract Given via Two Administration Routes (GWPD9901 EXT)
Guy, G. W., & Flint, M. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n03_03 · Cited by 62
Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado
Finseth, T. A., Hedeman, J. L., Brown, R. P., Johnson, K. I., Binder, M. S., & Kluger, B. M. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/874849 · Cited by 62
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Hunter, R. L., & Bing, G. (2007) · Current Neuropharmacology · doi:10.2174/157015907780077123 · Cited by 61
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats
Bürger, M. E., Fachineto, R., Alves, A. O., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.10.038 · Cited by 61
Inhibition of Adenylyl Cyclase Type 5 Prevents l-DOPA-Induced Dyskinesia in an Animal Model of Parkinson's Disease
Park, H.-Y., Kang, Y. M., Kang, Y. M., Park, T., Ryu, Y., Hwang, J.-H., Kim, Y.-H., Chung, B.-H., Nam, K., Kim, M. R., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-14.2014 · Cited by 59
Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo
Almási, R., Szőke, É., Bölcskei, K., Varga, A., Riedl, Z., Zoltán, S., Szolcsányi, J., & Pethö, G. (2008) · Life Sciences · doi:10.1016/j.lfs.2007.12.022 · Cited by 59
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats
Martinez, A. A., Macheda, T., Morgese, M. G., Trabace, L., & Giuffrida, A. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.12.006 · Cited by 57
Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?
Morales, P., Lago-Fernandez, A., Hurst, D. P., Sotudeh, N., Brailoiu, E., Reggio, P. H., Abood, M. E., & Jagerovic, N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00926 · Cited by 57
Δ9-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18
McHugh, D., Roskowski, D., Xie, S., & Bradshaw, H. B. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00162 · Cited by 53
Striatal CB 1 and D2 receptors regulate expression of each other, CRIP 1A and delta opioid systems
Blume, L. C., Bass, C. E., Childers, S. R., Dalton, G. D., Roberts, D. C. S., Richardson, J. M., Xiao, R., Selley, D. E., & Howlett, A. C. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12139 · Cited by 52
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by l -DOPA?
Bortolanza, M., Padovan‐Neto, F. E., Cavalcanti-Kwiatkoski, R., Pereira, M. D. S., Mitkovski, M., Raisman‐Vozari, R., & Bel, E. A. D. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0190 · Cited by 52
Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease
Peplow, P., & Martinez, B. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.237108 · Cited by 52
Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain
Valvassori, S. S., Bavaresco, D. V., Scaini, G., Varela, R. B., STRECK, E. L., Chagas, M. H. N., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-0886 · Cited by 51
Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function
Pisanu, A., Boi, L., Mulas, G., Spiga, S., Fenu, S., & Carta, A. R. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1874-4 · Cited by 49
Can Calcium Antagonists Provide a Neuroprotective Effect in Parkinson??s Disease?
Rodnitzky, R. L. (1999) · Drugs · doi:10.2165/00003495-199957060-00001 · Cited by 46
The Non-Psychoactive Plant Cannabinoid, Cannabidiol Affects Cholesterol Metabolism-Related Genes in Microglial Cells
Rimmerman, N., Juknat, A., Kozela, E., Levy, R., Bradshaw, H. B., & Vogel, Z. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9692-3 · Cited by 45
N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus
Gobira, P. H., Lima, I. V. D. A., Batista, L. A., de Oliveira, A. C., Resstel, L. B. M., Wotjak, C. T., de Aguiar, D. C., & Moreira, F. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691567 · Cited by 45
Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
Arellano, A. L., Papaseit, E., Romaguera, A., et al. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170413104516 · Cited by 44
Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity
Samarut, É., Nixon, J., Kundap, U. P., Drapeau, P., & Ellis, L. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00226 · Cited by 44
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease
Oeckl, P., Hengerer, B., & Ferger, B. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.010 · Cited by 43
Anticonvulsant activity of four oxygenated cannabidiol derivatives.
Carlini, E. A., Mechoulam, R., & Lander, N. (1975) · PubMed · Cited by 39
Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins
Schönhofen, P., de Medeiros, L. M., Bristot, I. J., Lopes, F. M., Bastiani, M. A. D., Kapczinski, F. P., Crippa, J. A. S., Castro, M. A. A., Parsons, R. B., & Klamt, F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8843-1 · Cited by 39
Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids
Cascio, M. G., & Pertwee, R. G. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0007 · Cited by 39
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Calabresi, P., & Standaert, D. G. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104579 · Cited by 39
Glial cells in Parkinson´s disease: protective or deleterious?
Domingues, A. V., Pereira, I. M., Vilaça-Faria, H., Salgado, A. J., Rodrigues, A. J., & Teixeira, F. G. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03584-x · Cited by 38
Endocannabinoid-LTP Mediated by CB1 and TRPV1 Receptors Encodes for Limited Occurrences of Coincident Activity in Neocortex
Cui, Y., Siaume‐Perez, S., & Venance, L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00182 · Cited by 36
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression
Malek, N., Kanavou, S., Lawton, M., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.05.022 · Cited by 36
Characterization and comparison of recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids † †Presented in abstract form in the following publications: Lam PMW, Smart D, Lambert DG. Anandamide but not Δ9-tetrahydrocannabinol activates recombinant human vanilloid receptors. Br J Anaesth 2003; 90: 418P; Lam PMW, Smart D, Lambert DG. Differences in the affinity of capsazepine at recombinant rat and human VR1 receptors. Br J Pharmacol 2003; 138: 220P.
Lam, P. M. W., McDonald, J. L., & Lambert, D. G. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei098 · Cited by 35
Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon
da Silva, J. A., Biagioni, A. F., Almada, R. C., Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., & Coimbra, N. C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.051 · Cited by 34
Cannabinoids for Neuropathic Pain
Fine, P. G., & Rosenfeld, M. J. (2014) · Current Pain and Headache Reports · doi:10.1007/s11916-014-0451-2 · Cited by 32
Temporal Changes of CB1 Cannabinoid Receptor in the Basal Ganglia as a Possible Structure-Specific Plasticity Process in 6-OHDA Lesioned Rats
Chaves-Kirsten, G. P., Mazucanti, C. H., Real, C. C., de Souza, B. M. B., Britto, L. R. G., & Torrão, A. D. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076874 · Cited by 28
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials
Pahwa, R., Isaacson, S., Shahed, J. J., Malaty, I. A., Deik, A., Johnson, R., & Patni, R. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.09.005 · Cited by 28
Chapter 2 Organized Trafficking of Anandamide and Related Lipids
Yates, M. L., & Barker, E. L. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(09)81002-9 · Cited by 27
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology
Wang, Y., Zhang, G., Sun, Y., Yao, L., Wang, H., Du, C., Zhang, L., & Liu, J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.03.020 · Cited by 15
Factors Associated With Dyskinesia in Parkinson's Disease in Mainland China
Zhou, X. C., Guo, J., Sun, Q., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00477 · Cited by 15
Adenosine A2A Receptor Modulates the Activity of Globus Pallidus Neurons in Rats
Diao, H., Xue, Y., Han, X., Wang, S., Liu, C., Chen, W., & Chen, L. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00897 · Cited by 10
Four main therapeutic keys for Parkinson's disease: A mini review.
Hernández-Baltazar, D., Nadella, R., Zavala-Flores, L. M., Rosas-Jarquín, C. D. J., Rovirosa-Hernández, M. D. J., & Villanueva-Olivo, A. (2019) · PubMed Central · doi:10.22038/ijbms.2019.33659.8025 · Cited by 5
Dyskinesias
Rascol, O., Fabre, N., Brefel‐Courbon, C., et al. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00025-3 · Cited by 4

Flagged first, then by citations

Research works printed but not linked: 4

Mechoulam, 2010, Pharmaceutical compositions comprising cannabidiol derivatives
Perez-Reyes, 1976, Intravenous administration of cannabinoids on intraocular pressure, 829
Pertwee, 2004, The pharmacology and therapeutic potential of cannabidiol, 32
Snider, 1985, Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia, Neurology, 35, 201

Sorted by citations

An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
Fragile X-associated tremor/ataxia syndrome: Pathophysiology and management
Hagerman, R., & Hagerman, P. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000954 · Cited by 40

See all 129

Authors: Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D.
Affiliations: Benemérita Universidad Autónoma de Puebla (MX)
Corresponding author: Limón, Ilhuicamina Daniel
ORCID: Patricio, Felipe
Patricio-Martínez, Aleidy
Limón, Ilhuicamina Daniel
Venue: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Published: 2020-12-15
Volume: 11
Pages: 595635-595635
ISSN: 1663-9812 (ISSN-L)
DOI: 10.3389/fphar.2020.595635
PMC: PMC7770114
OpenAlex: W3112818719
Cited by: 129
References: 240
Citations by year: 2026: 11 · 2025: 21 · 2024: 21 · 2023: 35 · 2022: 30 · 2021: 11
FWCI: 2.49
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Pharmacology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Consejo Nacional de Ciencia y Tecnología (2019-2020)
Benemérita Universidad Autónoma de Puebla (VIEP-BUAP 2019)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: cannabidiol, Parkinson's disease, neuroprotection, neuromodulation, endocannabinoid system, basal ganglia, nigrostriatal pathway, CB1 receptor, CB2 receptor, TRPV1 receptor, PPARγ, GPR55, GPR3, GPR6, GPR18, GPR30, GPR31, GPR34, GPR35, GPR37, GPR39, GPR40, GPR41, GPR

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks